The Optispan podcast often explores the science behind longevity and healthspan, discussing topics like DEXA scans, rapamycin dosing, and the role of optogenetics in understanding aging. However, the longevity field relies on more than just science—it requires a collective effort from researchers, engineers, entrepreneurs, and policymakers to turn discoveries into meaningful health advancements. In this episode, Matt talks with Dylan Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), about forming a bipartisan longevity caucus, shifting funding towards geroscience, and engaging policymakers to promote proactive healthcare.

Key Points:

This podcast features a conversation between Matt and Dylan Livingston about the creation of a bipartisan longevity science caucus and efforts to advocate for increased funding in geroscience research. They delve into the significance of involving policymakers to transition healthcare towards a proactive, preventative approach cantered on the biology of ageing.

• Introduction to A4LI: Dylan Livingston, CEO and founder of the Alliance for Longevity Initiatives (A4LI), discusses the organization's mission to lobby for the longevity biotech industry and advocate for legislation aimed at increasing healthy life expectancy in the U.S.
• Longevity Science Caucus: A major early success for A4LI was forming a bipartisan Longevity Science Caucus in the U.S. House of Representatives. This group raises awareness among policymakers about longevity science and helps identify congressional champions for the cause.
• Montana Right to Try Law Expansion: A4LI collaborated with Montana state senator Ken Bogner to pass a law expanding the Right to Try Act. This law allows patients to access therapeutics that have completed phase one clinical trials, increasing treatment options for those interested in longevity therapies.
• Engaging Policymakers: The podcast highlights the importance of shifting healthcare from reactive disease care to a proactive, preventative model. A4LI is actively working to increase funding for geroscience research and to engage with the FDA to facilitate the integration of longevity-focused therapeutics into clinical practice.
• A4LI's Advocacy Efforts: The organization's efforts include lobbying for more funding for the National Institute on ageing and advocating for regulatory changes to help biotech companies bring longevity therapies to market more effectively.
• A4LI Membership and Future Plans: A4LI has launched a membership system to involve the community and support its initiatives. Future plans include preparing for legislative asks and appropriations to further promote the importance and impact of longevity science.